These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 25883221)

  • 1. Prognostic value of a 92-probe signature in breast cancer.
    Akter S; Choi TG; Nguyen MN; Matondo A; Kim JH; Jo YH; Jo A; Shahid M; Jun DY; Yoo JY; Nguyen NN; Seo SW; Ali L; Lee JS; Yoon KS; Choe W; Kang I; Ha J; Kim J; Kim SS
    Oncotarget; 2015 Jun; 6(17):15662-80. PubMed ID: 25883221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    Iwamoto T; Kelly C; Mizoo T; Nogami T; Motoki T; Shien T; Taira N; Hayashi N; Niikura N; Fujiwara T; Doihara H; Matsuoka J
    Clin Breast Cancer; 2016 Apr; 16(2):95-100.e1. PubMed ID: 26631838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel MAPK-microRNA signature is predictive of hormone-therapy resistance and poor outcome in ER-positive breast cancer.
    Miller PC; Clarke J; Koru-Sengul T; Brinkman J; El-Ashry D
    Clin Cancer Res; 2015 Jan; 21(2):373-85. PubMed ID: 25370469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study.
    Mook S; Schmidt MK; Viale G; Pruneri G; Eekhout I; Floore A; Glas AM; Bogaerts J; Cardoso F; Piccart-Gebhart MJ; Rutgers ET; Van't Veer LJ;
    Breast Cancer Res Treat; 2009 Jul; 116(2):295-302. PubMed ID: 18661261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of 70-gene prognosis signature in node-negative breast cancer.
    Bueno-de-Mesquita JM; Linn SC; Keijzer R; Wesseling J; Nuyten DS; van Krimpen C; Meijers C; de Graaf PW; Bos MM; Hart AA; Rutgers EJ; Peterse JL; Halfwerk H; de Groot R; Pronk A; Floore AN; Glas AM; Van't Veer LJ; van de Vijver MJ
    Breast Cancer Res Treat; 2009 Oct; 117(3):483-95. PubMed ID: 18819002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A gene expression signature identifies two prognostic subgroups of basal breast cancer.
    Sabatier R; Finetti P; Cervera N; Lambaudie E; Esterni B; Mamessier E; Tallet A; Chabannon C; Extra JM; Jacquemier J; Viens P; Birnbaum D; Bertucci F
    Breast Cancer Res Treat; 2011 Apr; 126(2):407-20. PubMed ID: 20490655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An estrogen receptor (ER)-related signature in predicting prognosis of ER-positive breast cancer following endocrine treatment.
    Tang J; Cui Q; Zhang D; Liao X; Zhu J; Wu G
    J Cell Mol Med; 2019 Aug; 23(8):4980-4990. PubMed ID: 31124293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data.
    Győrffy B; Benke Z; Lánczky A; Balázs B; Szállási Z; Timár J; Schäfer R
    Breast Cancer Res Treat; 2012 Apr; 132(3):1025-34. PubMed ID: 21773767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population-based molecular prognosis of breast cancer by transcriptional profiling.
    Ma Y; Qian Y; Wei L; Abraham J; Shi X; Castranova V; Harner EJ; Flynn DC; Guo L
    Clin Cancer Res; 2007 Apr; 13(7):2014-22. PubMed ID: 17404081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers.
    Coutant C; Rouzier R; Qi Y; Lehmann-Che J; Bianchini G; Iwamoto T; Hortobagyi GN; Symmans WF; Uzan S; Andre F; de Thé H; Pusztai L
    Clin Cancer Res; 2011 Apr; 17(8):2591-601. PubMed ID: 21248301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raf kinase inhibitory protein role in the molecular subtyping of breast cancer.
    Al-Mulla F; Marafie M; Zea Tan T; Paul Thiery J
    J Cell Biochem; 2014 Mar; 115(3):488-97. PubMed ID: 24123286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes.
    Hanker LC; Rody A; Holtrich U; Pusztai L; Ruckhaeberle E; Liedtke C; Ahr A; Heinrich TM; Sänger N; Becker S; Karn T
    Breast Cancer Res Treat; 2013 Jan; 137(2):407-16. PubMed ID: 23242614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature.
    Mook S; Knauer M; Bueno-de-Mesquita JM; Retel VP; Wesseling J; Linn SC; Van't Veer LJ; Rutgers EJ
    Ann Surg Oncol; 2010 May; 17(5):1406-13. PubMed ID: 20094918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures.
    Cockburn JG; Hallett RM; Gillgrass AE; Dias KN; Whelan T; Levine MN; Hassell JA; Bane A
    BMC Cancer; 2016 Jul; 16():555. PubMed ID: 27469239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated gene expression profile predicts prognosis of breast cancer patients.
    Li LF; Xu XJ; Zhao Y; Liu ZB; Shen ZZ; Jin WR; Shao ZM
    Breast Cancer Res Treat; 2009 Jan; 113(2):231-7. PubMed ID: 18278552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.
    Györffy B; Lanczky A; Eklund AC; Denkert C; Budczies J; Li Q; Szallasi Z
    Breast Cancer Res Treat; 2010 Oct; 123(3):725-31. PubMed ID: 20020197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a prognostic LncRNA signature for ER-positive, ER-negative and triple-negative breast cancers.
    Liu D
    Breast Cancer Res Treat; 2020 Aug; 183(1):95-105. PubMed ID: 32601968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Refinement of breast cancer risk prediction with concordant leading edge subsets from prognostic gene signatures.
    Huang CC; Tu SH; Lien HH; Huang CS; Huang CJ; Lai LC; Tsai MH; Chuang EY
    Breast Cancer Res Treat; 2014 Sep; 147(2):353-70. PubMed ID: 25158930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model selection for prognostic time-to-event gene signature discovery with applications in early breast cancer data.
    Ahdesmäki M; Lancashire L; Proutski V; Wilson C; Davison TS; Harkin DP; Kennedy RD
    Stat Appl Genet Mol Biol; 2013 Oct; 12(5):619-35. PubMed ID: 24077567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 16 Yin Yang gene expression ratio signature for ER+/node- breast cancer.
    Xu W; Jia G; Cai N; Huang S; Davie JR; Pitz M; Banerji S; Murphy L
    Int J Cancer; 2017 Mar; 140(6):1413-1424. PubMed ID: 27925180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.